Nous-209 neoantigen vaccine for cancer prevention in Lynch syndrome carriers: a phase 1b/2 trial

Cancer interception is a preventative approach aiming to reduce cancer incidence by targeting precancers and early-stage cancers. Lynch syndrome (LS) is a prevalent hereditary cancer syndrome affecting ~1 in 300 individuals, with an overall lifetime cancer risk as high as 80%. LS is caused by germline mutations in the DNA mismatch repair genes, leading to microsatellite instability (MSI) and accumulation of shared mutations. When these occur in coding regions, they generate frameshift peptides (FSPs). Nous-209 is a neoantigen-directed immunotherapy based on a heterologous prime boost using great ape adenovirus and modified vaccinia virus Ankara encoding 209 FSPs shared across MSI neoplasms. We present the…

• NI
  National Institutes of Health

  Awards: CA088084, CA016672, RP170259, UG1 CA242609, CA221707, P30 CA016672
• UO
  University of Texas MD Anderson Cancer Center

  Awards: CA016672, P50 CA221707, P30 CA016672
• NC
  National Cancer Institute

  Awards: P30 CA016672, RP170259, CA016672, CA088084, CA221707, P50 CA221707